The role of fibrinogen in the hemostatic process is crucial, but it is only one facet of a complex process. The hemostatic cascade involves the coordinated interaction of endothelial cells, platelets, and plasma proteins, leading to well-ordered activation and deactivation between coagulation factors. This process can be summarized in four key phases: initiation, amplification, propagation, and stabilization.

Move your mouse over the image and click on a factor to learn more about its role in the coagulation process.

Hoffman et al. Thromb Haemost 2001;85(6):958–65.

Monroe et al. Arterioscler Thromb Vasc Biol 2006;26(1):41–48.

Important Safety Information

RiaSTAP®, Fibrinogen Concentrate (Human), is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products.

Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving RiaSTAP; weigh the benefits of administration versus the risks of thrombosis.

RiaSTAP is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most serious adverse reactions observed are thrombotic episodes (pulmonary embolism, myocardial infarction, deep vein thrombosis) and anaphylactic reactions. The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache.


RIASTAP is indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Please see full prescribing information for RiaSTAP.

To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or